Analyst Reco. Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Market Closed - Nyse Other stock markets 04:00:02 2024-05-24 pm EDT			5-day change	1st Jan Change
16.12 ^USD	-0.98%		-4.62%	-15.60%

May. 16	Transcript : Arcus Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
May. 08	Transcript : Arcus Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating	Jan. 30	MT
Wedbush Lowers Arcus Biosciences' PT to $30 From $36 After Announced Plans to Discontinue Enrollment for Phase 3 ARC-10 Study; Keeps Outperform Rating	Jan. 30	MT
Morgan Stanley Cuts Price Target on Arcus Biosciences to $35 From $38, Maintains Overweight Rating	Nov. 13	MT
Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating	Nov. 08	MT
Citigroup Adjusts Price Target on Arcus Biosciences to $44 From $41, Maintains Buy Rating	23-08-24	MT
Morgan Stanley Trims Price Target on Arcus Biosciences to $38 From $40, Maintains Overweight Rating	23-08-08	MT
Cantor Fitzgerald Reiterates Arcus Biosciences' Overweight Rating, $46 Price Target	23-07-12	MT
Citigroup Adjusts Arcus Biosciences Price Target to $41 From $40, Maintains Buy Rating	23-05-26	MT
Barclays Adjusts Price Target on Arcus Biosciences to $35 From $60, Maintains Overweight Rating	22-12-21	MT
Citigroup Adjusts Arcus Biosciences' Price Target to $42 From $37, Keeps Buy Rating	22-12-20	MT
Citigroup Lowers Price Target on Arcus Biosciences to $37 From $40, Maintains Buy Rating	22-11-23	MT
BofA Securities Starts Arcus Biosciences at Neutral With $33 Price Target	22-11-18	MT
SVB Securities Adjusts Price Target on Arcus Biosciences to $38 From $40, Maintains Outperform Rating	22-11-03	MT
Berenberg Bank Adjusts Arcus Biosciences Price Target to $60 From $68, Maintains Buy Rating	22-11-03	MT
Morgan Stanley Starts Arcus Biosciences at Overweight With $40 Price Target	22-10-11	MT
Goldman Sachs Adjusts Arcus Biosciences' Price Target to $29 From $28, Maintains Neutral Rating	22-08-04	MT
SVB Securities Adjusts Arcus Biosciences' Price Target to $49 from $66, Keeps Outperform Rating	22-08-04	MT
Wedbush Adjusts Price Target on Arcus Biosciences to $36 From $42, Keeps Outperform Rating	22-08-04	MT
Truist Securities Adjusts Arcus Biosciences' Price Target to $50 from $77, Keeps Buy Rating	22-07-08	MT
Goldman Sachs Adjusts Arcus Biosciences Price Target to $28 From $48, Maintains Neutral Rating	22-05-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Analyst Reco.

Filters